Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Preview or download our range of resources designed for healthcare professionals to help patients get started on GILENYA. If you would like to receive copies of any of these materials, please contact your Key Account Manager.

 

Image of the Young person's guide to Gilenya patient booklet.

THE YOUNG PERSON'S GUIDE TO GILENYA

A booklet to help your paediatric patients understand more about their treatment.

Preview


GILENYA PATIENT BOOKLET

A booklet for you to give to your patients who have been prescribed GILENYA. The booklet provides background information about GILENYA, important information about taking GILENYA, and practical advice about wellbeing while on treatment.

Preview

Image of the What to expect when starting Gilenya patient video.

WHAT TO EXPECT WHEN STARTING GILENYA

A video for patients prescribed GILENYA to help them understand what to expect during their first dose.

Watch


Image of the Recognising your symptoms patient booklet.

RECOGNISING YOUR MS SYMPTOMS

A guide for your MS patients to help them recognise MS symptoms and what to do in case they think they are having a relapse.

Preview


Image of the MS symptom tracker patient booklet.

MS RELAPSE RECORDER

A resource for your patients to record and track their MS symptoms.

Preview

Image of the PARADIGMS study summary video.

PARADIGMS STUDY VIDEO

An animated overview of the PARADIGMS study, a landmark phase III trial of GILENYA in paediatric patients with RRMS.

Watch


Image of the PARADIGMS study summary video.

GILENYA DISCUSSION GUIDE

A guide for you to use with your patients who have been prescribed GILENYA. The guide helps you introduce GILENYA and explain information that patients need to know before commencing treatment.

Preview


PATIENT, PARENT AND CAREGIVER GUIDE

A booklet for you to give to patients who have been prescribed GILENYA, or their parents or caregivers. The booklet explains what GILENYA is, and contains important information for before, during, and after taking GILENYA.

View

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

PREGNANCY-SPECIFIC PATIENT REMINDER CARD

A card to give to patients which explains the warnings and contraindications related to pregnancy associated with GILENYA.

View

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

PRESCRIBER'S CHECKLIST

A checklist for prescribers listing important points to remember before, during and after a patient has been prescribed GILENYA.

View

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

SUMMARY OF PRODUCT CHARACTERISTICS FOR GILENYA

Summary of product characteristics for GILENYA.

View

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

Gd+: gadolinium enhancing; HCP: healthcare professional; MRI: magnetic resonance imaging; MS: multiple sclerosis; RES: rapidly evolving severe; RMP: risk minimisation plan; RRMS: relapsing remitting multiple sclerosis.

Indication: GILENYA is indicated as a single disease modifying therapy in highly active RRMS for the following groups of adult patients and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with ≥1 disease modifying therapy, or patients with RES RRMS defined by ≥2 disabling relapses in 1 year, and with 1 or more Gd+ lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.1

Reference

  1. GILENYA (fingolimod) Summary of Product Characteristics.
GIL19-C053e(1) June 2020
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]